Helix BioPharma Corp. (TSE:HBP – Get Free Report)’s stock price crossed above its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of C$1.47 and traded as high as C$1.70. Helix BioPharma shares last traded at C$1.70, with a volume of 1,315 shares changing hands.
Helix BioPharma Stock Up 3.9%
The firm has a market cap of C$142.83 million, a PE ratio of -46.75 and a beta of 0.43. The company has a debt-to-equity ratio of 2.44, a quick ratio of 1.03 and a current ratio of 0.45. The company’s 50-day simple moving average is C$1.48 and its two-hundred day simple moving average is C$1.72.
Helix BioPharma (TSE:HBP – Get Free Report) last released its quarterly earnings data on Friday, June 12th. The biopharmaceutical company reported C($0.01) earnings per share (EPS) for the quarter. On average, analysts predict that Helix BioPharma Corp. will post -0.11 earnings per share for the current fiscal year.
Helix BioPharma Company Profile
Helix BioPharma is an oncology company that innovates from strength to bring near-term solutions for today’s hardest-to-treat cancers. The Company’s pipeline is led by Tumor Defense Breaker¿ L-DOS47, a clinical-stage antibody-enzyme conjugate designed to prime CEACAM6-expressing tumors for increased sensitivity to therapy and augment the effectiveness of today’s front-running anti-cancer treatments. L-DOS47 has completed Phase Ib studies in non-small cell lung cancer (NSCLC) and shares its CEACAM6-targeting foundation with Helix’s next-generation bi-specific antibody-drug conjugates (ADCs), currently in discovery.
Further Reading
- Five stocks we like better than Helix BioPharma
- Sony and TSMC’s $4.7 Billion Venture Is About More Than Camera Sensors
- Quantum Leaps: Debt-Free as AI Storage Demand Accelerates
- NVIDIA’s $500 Billion GPU Financing Deal Fuels Path Toward $270
- Sandisk’s Margins Look Like Software. Can They Last?
Receive News & Ratings for Helix BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Helix BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
